News | February 15, 2025
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Subscribe To Our Newsletter & Stay Updated
